Class summary at a glance.

Every drug in the Potassium Channel Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $126.7Mcombined across class
Total Rx claims: 175K34K unique beneficiaries
Generic mfrs (active): 5across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Dalfampridine

Brand: AMPYRA · 175K Part D claims (CY24) · 34K beneficiaries · First FDA approval: 2010-03-01

5 generic mfrs 273 plans require PA

Low NADAC$0.386

→

Avg plan cost$0.386

Part D spend $126.7M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.